BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16385573)

  • 1. Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid.
    Loddenkemper C; Keller S; Hanski ML; Cao M; Jahreis G; Stein H; Zeitz M; Hanski C
    Int J Cancer; 2006 Jun; 118(11):2750-7. PubMed ID: 16385573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers.
    van Gorkom BA; van der Meer R; Boersma-van Ek W; Termont DS; de Vries EG; Kleibeuker JH
    Scand J Gastroenterol; 2002 Aug; 37(8):965-71. PubMed ID: 12229974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps.
    Batta AK; Salen G; Holubec H; Brasitus TA; Alberts D; Earnest DL
    Cancer Res; 1998 Apr; 58(8):1684-7. PubMed ID: 9563483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells.
    Shah SA; Volkov Y; Arfin Q; Abdel-Latif MM; Kelleher D
    Int J Cancer; 2006 Feb; 118(3):532-9. PubMed ID: 16106402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
    Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro.
    Serfaty L
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S53-60. PubMed ID: 23141895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids.
    Stenman LK; Holma R; Eggert A; Korpela R
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G227-34. PubMed ID: 23203158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice.
    Kohno H; Suzuki R; Yasui Y; Miyamoto S; Wakabayashi K; Tanaka T
    Clin Cancer Res; 2007 Apr; 13(8):2519-25. PubMed ID: 17438113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis.
    Lajczak-McGinley NK; Porru E; Fallon CM; Smyth J; Curley C; McCarron PA; Tambuwala MM; Roda A; Keely SJ
    Physiol Rep; 2020 Jun; 8(12):e14456. PubMed ID: 32562381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study.
    Ochsenkühn T; Marsteller I; Hay U; Diebold J; Paumgartner G; Göke B; Sackmann M
    Digestion; 2003; 68(4):209-16. PubMed ID: 14707397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats.
    Narisawa T; Fukaura Y; Terada K; Sekiguchi H
    J Exp Clin Cancer Res; 1999 Jun; 18(2):259-66. PubMed ID: 10464717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ursodeoxycholic acid on azoxymethane-induced aberrant crypt foci formation in rat colon: in vitro potential role of intracellular Ca2+.
    Momen MA; Monden Y; Houchi H; Umemoto A
    J Med Invest; 2002 Feb; 49(1-2):67-73. PubMed ID: 11901763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bile acids on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced aberrant crypt foci and DNA adduct formation in the rat colon.
    Ueyama Y; Monden Y; He XB; Lin CX; Momen MA; Mimura S; Umemoto A
    J Exp Clin Cancer Res; 2002 Dec; 21(4):577-83. PubMed ID: 12636105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities.
    Paolini M; Pozzetti L; Montagnani M; Potenza G; Sabatini L; Antelli A; Cantelli-Forti G; Roda A
    Hepatology; 2002 Aug; 36(2):305-14. PubMed ID: 12143038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression.
    Kim YJ; Lee JS; Hong KS; Chung JW; Kim JH; Hahm KB
    Cancer Prev Res (Phila); 2010 Aug; 3(8):963-74. PubMed ID: 20628001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development.
    Wali RK; Stoiber D; Nguyen L; Hart J; Sitrin MD; Brasitus T; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1316-21. PubMed ID: 12433708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile acids modulate the Golgi membrane fission process via a protein kinase Ceta and protein kinase D-dependent pathway in colonic epithelial cells.
    Byrne AM; Foran E; Sharma R; Davies A; Mahon C; O'Sullivan J; O'Donoghue D; Kelleher D; Long A
    Carcinogenesis; 2010 Apr; 31(4):737-44. PubMed ID: 20093383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral ursodeoxycholic acid on bile acids tolerance tests in healthy dogs.
    Abraham LA; Charles JA; Holloway SA
    Aust Vet J; 2004 Mar; 82(3):157-60. PubMed ID: 15088982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
    Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
    Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.